Cogent Biosciences to Participate in the Guggenheim Biotech Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Wednesday,
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.
After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...
Biotech Showcase™ 2025 Opens the Year with More than 3,000 Attendees, 340+ Presenting Companies, 1,020+ Investors and 85+ Members of the Media ...
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
24/7 Wall St. on MSN6d
I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the GameThe biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...
Curie.Bio, the biotech accelerator and investment firm, has raised another $340 million to invest in startups.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...
Biotechnology venture capital is recovering from its slide and investors are expressing optimism about 2025, even as they ...
Biotech has a big footprint in Massachusetts, and according to a 2023 report, women make up less than 6% of leadership roles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback